European Commission expands Imcrivee (setmelanotide) marketing authorization to include children as young as 2 years old living with BBS or POMC, PCSK1, or LEPR deficiency
Rhythm Pharmaceuticals, Inc. announced that the European Commission (EC) expanded the marketing authorization for Imcivree (setmelanotide) to include children between 2 and younger than 6 years old with obesity due to Bardet Biedl syndrome (BBS) or pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency
“Today marks what we believe to be an important milestone for European patients with BBS and POMC/LEPR deficiencies ages 2 to 6, who now have the opportunity to address the severe and insatiable hunger and early onset obesity associated with their conditions at an early age,” said Yann Mazabraud, Executive Vice President, Head of International at Rhythm Pharmaceuticals. “Early-onset obesity that goes untreated can manifest in multiple comorbidities and negatively affect quality of life and life expectancy. For the first time, physicians and patients in Europe may have the opportunity to access what we believe is a meaningful treatment option for children as young as 2 years old.”
Imcivree is the first-ever authorized precision medicine in the European Union for control of hunger and treatment of obesity in adults and children, now as young as 2 years old, living with BBS or POMC, PCSK1, or LEPR deficiency.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
4 mins